These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31820972)

  • 1. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography.
    Kamsri P; Hanwarinroj C; Phusi N; Pornprom T; Chayajarus K; Punkvang A; Suttipanta N; Srimanote P; Suttisintong K; Songsiriritthigul C; Saparpakorn P; Hannongbua S; Rattanabunyong S; Seetaha S; Choowongkomon K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Chen Z; Zhu W; Blood RA; Takebayashi Y; Hinchliffe P; Mulholland AJ; Spencer J; Pungpo P
    J Chem Inf Model; 2020 Jan; 60(1):226-234. PubMed ID: 31820972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
    Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
    Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
    He X; Alian A; Ortiz de Montellano PR
    Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
    Saharan VD; Mahajan SS
    Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.
    Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP
    ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New coumarin linked thiazole derivatives as antimycobacterial agents: Design, synthesis, enoyl acyl carrier protein reductase (InhA) inhibition and molecular modeling.
    Kassem AF; Sabt A; Korycka-Machala M; Shaldam MA; Kawka M; Dziadek B; Kuzioła M; Dziadek J; Batran RZ
    Bioorg Chem; 2024 Sep; 150():107511. PubMed ID: 38870705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel and potent InhA direct inhibitors by ensemble docking-based virtual screening and biological assays.
    Zhang Q; Han J; Zhu Y; Yu F; Hu X; Tong HHY; Liu H
    J Comput Aided Mol Des; 2023 Dec; 37(12):695-706. PubMed ID: 37642861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
    Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
    J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First triclosan-based macrocyclic inhibitors of InhA enzyme.
    Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
    Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
    Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
    Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
    Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
    J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
    Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
    Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
    Lokesh BVS; Prasad YR; Shaik AB
    Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme.
    Venugopala KN; Chandrashekharappa S; Deb PK; Tratrat C; Pillay M; Chopra D; Al-Shar'i NA; Hourani W; Dahabiyeh LA; Borah P; Nagdeve RD; Nayak SK; Padmashali B; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Haroun M; Shashikanth S; Mohanlall V; Mailavaram R
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1472-1487. PubMed ID: 34210233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.
    Stigliani JL; Bernardes-Génisson V; Bernadou J; Pratviel G
    Org Biomol Chem; 2012 Aug; 10(31):6341-9. PubMed ID: 22751934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances and Structural Features of Enoyl-ACP Reductase Inhibitors of Mycobacterium tuberculosis.
    Inturi B; Pujar GV; Purohit MN
    Arch Pharm (Weinheim); 2016 Nov; 349(11):817-826. PubMed ID: 27775177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.